The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer

Charles J. Rosser, Deborah A. Kuban, Lawrence B. Levy, Ramsey Chichakli, Alan Pollack, Andrew K. Lee, Louis L. Pisters

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Purpose: We characterize the prostate-specific antigen (PSA) bounce in patients who underwent external beam radiation therapy for prostate cancer and correlate the PSA bounce with the development of biochemical disease progression. Materials and Methods: In this study 964 patients received full dose radiation therapy alone. Followup PSA values were obtained 3 months after completion of radiotherapy and every 3 to 6 months thereafter. Median followup of the entire study group was 48 months. All time intervals were calculated from the completion date of radiation therapy. PSA bounce was defined as an initial increase in serum PSA of at least 0.5 ng./ml., followed by a decrease to pre-bounce baseline serum PSA values no more than 60 months after external beam radiation therapy. Results: Of the 964 patients 119 (12%) had a PSA bounce. PSA bounce was unrelated to age, race, pretreatment PSA, Gleason score, clinical T stage or radiation dose. Mean time to PSA bounce was 9 months from the time of therapy. The respective 1 and 5-year biochemical disease-free survival rates were 100% and 82.1% for patients with PSA bounce and 93.9% and 57.7% for those without PSA bounce (p = 0.0001). Conclusions: Of men with prostate cancer treated with external beam radiation therapy 12% experienced a transient increase in PSA (PSA bounce) followed by a return to pre-bounce levels after radiation. The PSA bounce phenomenon was not predictive of time to biochemical recurrence.

Original languageEnglish
Pages (from-to)2001-2005
Number of pages5
JournalJournal of Urology
Volume168
Issue number5
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Radiation
Radiotherapy
Neoplasm Grading
Serum
Disease-Free Survival
Disease Progression

Keywords

  • Prostate-specific antigen
  • Prostatic neoplasms
  • Radiotherapy

ASJC Scopus subject areas

  • Urology

Cite this

Rosser, C. J., Kuban, D. A., Levy, L. B., Chichakli, R., Pollack, A., Lee, A. K., & Pisters, L. L. (2002). The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. Journal of Urology, 168(5), 2001-2005.

The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. / Rosser, Charles J.; Kuban, Deborah A.; Levy, Lawrence B.; Chichakli, Ramsey; Pollack, Alan; Lee, Andrew K.; Pisters, Louis L.

In: Journal of Urology, Vol. 168, No. 5, 01.11.2002, p. 2001-2005.

Research output: Contribution to journalArticle

Rosser, CJ, Kuban, DA, Levy, LB, Chichakli, R, Pollack, A, Lee, AK & Pisters, LL 2002, 'The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer', Journal of Urology, vol. 168, no. 5, pp. 2001-2005.
Rosser, Charles J. ; Kuban, Deborah A. ; Levy, Lawrence B. ; Chichakli, Ramsey ; Pollack, Alan ; Lee, Andrew K. ; Pisters, Louis L. / The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. In: Journal of Urology. 2002 ; Vol. 168, No. 5. pp. 2001-2005.
@article{3fb85066f729499782f312ae9f26e363,
title = "The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer",
abstract = "Purpose: We characterize the prostate-specific antigen (PSA) bounce in patients who underwent external beam radiation therapy for prostate cancer and correlate the PSA bounce with the development of biochemical disease progression. Materials and Methods: In this study 964 patients received full dose radiation therapy alone. Followup PSA values were obtained 3 months after completion of radiotherapy and every 3 to 6 months thereafter. Median followup of the entire study group was 48 months. All time intervals were calculated from the completion date of radiation therapy. PSA bounce was defined as an initial increase in serum PSA of at least 0.5 ng./ml., followed by a decrease to pre-bounce baseline serum PSA values no more than 60 months after external beam radiation therapy. Results: Of the 964 patients 119 (12{\%}) had a PSA bounce. PSA bounce was unrelated to age, race, pretreatment PSA, Gleason score, clinical T stage or radiation dose. Mean time to PSA bounce was 9 months from the time of therapy. The respective 1 and 5-year biochemical disease-free survival rates were 100{\%} and 82.1{\%} for patients with PSA bounce and 93.9{\%} and 57.7{\%} for those without PSA bounce (p = 0.0001). Conclusions: Of men with prostate cancer treated with external beam radiation therapy 12{\%} experienced a transient increase in PSA (PSA bounce) followed by a return to pre-bounce levels after radiation. The PSA bounce phenomenon was not predictive of time to biochemical recurrence.",
keywords = "Prostate-specific antigen, Prostatic neoplasms, Radiotherapy",
author = "Rosser, {Charles J.} and Kuban, {Deborah A.} and Levy, {Lawrence B.} and Ramsey Chichakli and Alan Pollack and Lee, {Andrew K.} and Pisters, {Louis L.}",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "168",
pages = "2001--2005",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer

AU - Rosser, Charles J.

AU - Kuban, Deborah A.

AU - Levy, Lawrence B.

AU - Chichakli, Ramsey

AU - Pollack, Alan

AU - Lee, Andrew K.

AU - Pisters, Louis L.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Purpose: We characterize the prostate-specific antigen (PSA) bounce in patients who underwent external beam radiation therapy for prostate cancer and correlate the PSA bounce with the development of biochemical disease progression. Materials and Methods: In this study 964 patients received full dose radiation therapy alone. Followup PSA values were obtained 3 months after completion of radiotherapy and every 3 to 6 months thereafter. Median followup of the entire study group was 48 months. All time intervals were calculated from the completion date of radiation therapy. PSA bounce was defined as an initial increase in serum PSA of at least 0.5 ng./ml., followed by a decrease to pre-bounce baseline serum PSA values no more than 60 months after external beam radiation therapy. Results: Of the 964 patients 119 (12%) had a PSA bounce. PSA bounce was unrelated to age, race, pretreatment PSA, Gleason score, clinical T stage or radiation dose. Mean time to PSA bounce was 9 months from the time of therapy. The respective 1 and 5-year biochemical disease-free survival rates were 100% and 82.1% for patients with PSA bounce and 93.9% and 57.7% for those without PSA bounce (p = 0.0001). Conclusions: Of men with prostate cancer treated with external beam radiation therapy 12% experienced a transient increase in PSA (PSA bounce) followed by a return to pre-bounce levels after radiation. The PSA bounce phenomenon was not predictive of time to biochemical recurrence.

AB - Purpose: We characterize the prostate-specific antigen (PSA) bounce in patients who underwent external beam radiation therapy for prostate cancer and correlate the PSA bounce with the development of biochemical disease progression. Materials and Methods: In this study 964 patients received full dose radiation therapy alone. Followup PSA values were obtained 3 months after completion of radiotherapy and every 3 to 6 months thereafter. Median followup of the entire study group was 48 months. All time intervals were calculated from the completion date of radiation therapy. PSA bounce was defined as an initial increase in serum PSA of at least 0.5 ng./ml., followed by a decrease to pre-bounce baseline serum PSA values no more than 60 months after external beam radiation therapy. Results: Of the 964 patients 119 (12%) had a PSA bounce. PSA bounce was unrelated to age, race, pretreatment PSA, Gleason score, clinical T stage or radiation dose. Mean time to PSA bounce was 9 months from the time of therapy. The respective 1 and 5-year biochemical disease-free survival rates were 100% and 82.1% for patients with PSA bounce and 93.9% and 57.7% for those without PSA bounce (p = 0.0001). Conclusions: Of men with prostate cancer treated with external beam radiation therapy 12% experienced a transient increase in PSA (PSA bounce) followed by a return to pre-bounce levels after radiation. The PSA bounce phenomenon was not predictive of time to biochemical recurrence.

KW - Prostate-specific antigen

KW - Prostatic neoplasms

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036837239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036837239&partnerID=8YFLogxK

M3 - Article

VL - 168

SP - 2001

EP - 2005

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -